Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) EPS (Weighted Average and Diluted) (2020 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$2.55 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 2.0% to -$2.55 in Q4 2025 year-over-year; TTM through Dec 2025 was -$12.85, a 41.32% increase, with the full-year FY2025 number at -$12.85, up 41.32% from a year prior.
  • EPS (Weighted Average and Diluted) was -$2.55 for Q4 2025 at Madrigal Pharmaceuticals, up from -$5.08 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$1.9 in Q2 2025 to a low of -$7.38 in Q1 2024.
  • A 5-year average of -$4.33 and a median of -$4.19 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 74.47% in 2024, then skyrocketed 73.24% in 2025.
  • Madrigal Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$3.79 in 2021, then plummeted by 31.4% to -$4.98 in 2022, then decreased by 14.86% to -$5.72 in 2023, then surged by 56.29% to -$2.5 in 2024, then fell by 2.0% to -$2.55 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's EPS (Weighted Average and Diluted) are -$2.55 (Q4 2025), -$5.08 (Q3 2025), and -$1.9 (Q2 2025).